130 related articles for article (PubMed ID: 21745127)
1. Can an early weight management program (WMP) prevent olanzapine (OLZ)-induced disturbances in body weight, blood glucose and lipid metabolism? Twenty-four- and 48-week results from a 6-month randomized trial.
Cordes J; Thünker J; Regenbrecht G; Zielasek J; Correll CU; Schmidt-Kraepelin C; Lange-Asschenfeldt C; Agelink MW; Kahl KG; Gaebel W; Klimke A; Hauner H
World J Biol Psychiatry; 2014 Apr; 15(3):229-41. PubMed ID: 21745127
[TBL] [Abstract][Full Text] [Related]
2. Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: A 12-week randomized controlled clinical trial.
Kwon JS; Choi JS; Bahk WM; Yoon Kim C; Hyung Kim C; Chul Shin Y; Park BJ; Geun Oh C
J Clin Psychiatry; 2006 Apr; 67(4):547-53. PubMed ID: 16669719
[TBL] [Abstract][Full Text] [Related]
3. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial.
Baptista T; Martínez J; Lacruz A; Rangel N; Beaulieu S; Serrano A; Arapé Y; Martinez M; de Mendoza S; Teneud L; Hernández L
Can J Psychiatry; 2006 Mar; 51(3):192-6. PubMed ID: 16618011
[TBL] [Abstract][Full Text] [Related]
4. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.
Henderson DC; Copeland PM; Daley TB; Borba CP; Cather C; Nguyen DD; Louie PM; Evins AE; Freudenreich O; Hayden D; Goff DC
Am J Psychiatry; 2005 May; 162(5):954-62. PubMed ID: 15863798
[TBL] [Abstract][Full Text] [Related]
5. Olanzapine/Samidorphan in Young Adults With Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder Who Are Early in Their Illness: Results of the Randomized, Controlled ENLIGHTEN-Early Study.
Kahn RS; Kane JM; Correll CU; Arevalo C; Simmons A; Graham C; Yagoda S; Hu B; McDonnell D
J Clin Psychiatry; 2023 Mar; 84(3):. PubMed ID: 36946605
[No Abstract] [Full Text] [Related]
6. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.
Wu RR; Zhao JP; Guo XF; He YQ; Fang MS; Guo WB; Chen JD; Li LH
Am J Psychiatry; 2008 Mar; 165(3):352-8. PubMed ID: 18245179
[TBL] [Abstract][Full Text] [Related]
7. Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia.
Bushe C; Sniadecki J; Bradley AJ; Poole Hoffmann V
J Psychopharmacol; 2010 Jul; 24(7):1001-9. PubMed ID: 19240085
[TBL] [Abstract][Full Text] [Related]
8. Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions.
Birkenaes AB; Birkeland KI; Engh JA; Faerden A; Jonsdottir H; Ringen PA; Friis S; Opjordsmoen S; Andreassen OA
J Clin Psychopharmacol; 2008 Apr; 28(2):132-7. PubMed ID: 18344722
[TBL] [Abstract][Full Text] [Related]
9. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study.
Meyer JM; Pandina G; Bossie CA; Turkoz I; Greenspan A
Clin Ther; 2005 Dec; 27(12):1930-41. PubMed ID: 16507379
[TBL] [Abstract][Full Text] [Related]
10. The effect of naltrexone on body fat mass in olanzapine-treated schizophrenic or schizoaffective patients: a randomized double-blind placebo-controlled pilot study.
Taveira TH; Wu WC; Tschibelu E; Borsook D; Simonson DC; Yamamoto R; Langleben DD; Swift R; Elman I
J Psychopharmacol; 2014 Apr; 28(4):395-400. PubMed ID: 24218048
[TBL] [Abstract][Full Text] [Related]
11. Effects of a 10-week weight control program on obese patients with schizophrenia or schizoaffective disorder: a 12-month follow up.
Chen CK; Chen YC; Huang YS
Psychiatry Clin Neurosci; 2009 Feb; 63(1):17-22. PubMed ID: 19067997
[TBL] [Abstract][Full Text] [Related]
12. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
Lindenmayer JP; Czobor P; Volavka J; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
Am J Psychiatry; 2003 Feb; 160(2):290-6. PubMed ID: 12562575
[TBL] [Abstract][Full Text] [Related]
13. Metabolic parameters and long-term antipsychotic treatment: a comparison between patients treated with clozapine or olanzapine.
Feng S; Melkersson K
Neuro Endocrinol Lett; 2012; 33(5):493-8. PubMed ID: 23090266
[TBL] [Abstract][Full Text] [Related]
14. Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine.
Peuskens J; De Hert M; Mortimer A;
Int Clin Psychopharmacol; 2007 May; 22(3):145-52. PubMed ID: 17414740
[TBL] [Abstract][Full Text] [Related]
15. [Atypical antipsychotic-associated impaired glucose tolerance].
Boku S; Sugawara Y; Nakayama M; Homma H; Iwasaki S; Matsubara S
Seishin Shinkeigaku Zasshi; 2005; 107(8):811-9. PubMed ID: 16259405
[TBL] [Abstract][Full Text] [Related]
16. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning.
Kinon BJ; Noordsy DL; Liu-Seifert H; Gulliver AH; Ascher-Svanum H; Kollack-Walker S
J Clin Psychopharmacol; 2006 Oct; 26(5):453-61. PubMed ID: 16974184
[TBL] [Abstract][Full Text] [Related]
17. Weight gain, dyslipidemia and altered parameters for metabolic syndrome on first episode psychotic patients after six-month follow-up.
Attux C; Quintana MI; Chaves AC
Braz J Psychiatry; 2007 Dec; 29(4):346-9. PubMed ID: 17992359
[TBL] [Abstract][Full Text] [Related]
18. Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine.
Kryzhanovskaya LA; Xu W; Millen BA; Acharya N; Jen KY; Osuntokun O
J Child Adolesc Psychopharmacol; 2012 Apr; 22(2):157-65. PubMed ID: 22372514
[TBL] [Abstract][Full Text] [Related]
19. A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: the PLATYPUS Study.
Karagianis J; Grossman L; Landry J; Reed VA; de Haan L; Maguire GA; Hoffmann VP; Milev R
Schizophr Res; 2009 Aug; 113(1):41-8. PubMed ID: 19535229
[TBL] [Abstract][Full Text] [Related]
20. A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extension.
Kahn RS; Silverman BL; DiPetrillo L; Graham C; Jiang Y; Yin J; Simmons A; Bhupathi V; Yu B; Yagoda S; Hopkinson C; McDonnell D
Schizophr Res; 2021 Jun; 232():45-53. PubMed ID: 34015555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
